Response and Resistance to BRAF Inhibition in Gliomas: Roadblocks Ahead?

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Jan 26

PMID 36698391

Authors

Monica Capogiri

Andrea J De Micheli

Alvaro Lassaletta

Denise P Munoz

Jean-Philippe Coppe

Sabine Mueller

Ana S Guerreiro Stucklin

Affiliations

Soon will be listed here.

Abstract

BRAF represents the most common BRAF mutation in all human cancers. Among central nervous system (CNS) tumors, BRAF is mostly found in pediatric low-grade gliomas (pLGG, ~20%) and, less frequently, in pediatric high-grade gliomas (pHGG, 5-15%) and adult glioblastomas (GBM, ~5%). The integration of BRAF inhibitors (BRAFi) in the treatment of patients with gliomas brought a paradigm shift to clinical care. However, not all patients benefit from treatment due to intrinsic or acquired resistance to BRAF inhibition. Defining predictors of response, as well as developing strategies to prevent resistance to BRAFi and overcome post-BRAFi tumor progression/rebound growth are some of the main challenges at present in the field. In this review, we outline current achievements and limitations of BRAF inhibition in gliomas, with a special focus on potential mechanisms of resistance. We discuss future directions of targeted therapy for BRAF mutated gliomas, highlighting how insights into resistance to BRAFi could be leveraged to improve outcomes.

Citing Articles

BRAF V600E in a preclinical model of pleomorphic Xanthoastrocytoma: Analysis of the tumor microenvironment and immune cell infiltration dynamics .

Canella A, Nazzaro M, Artomov M, Rao Venkata L, Thomas D, Lyberger J Mol Ther Oncol. 2024; 32(2):200808.

PMID: 38784952 PMC: 11112369. DOI: 10.1016/j.omton.2024.200808.

Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: A modified Delphi approach to build international consensus-based definitions-International Pediatric Low-Grade Glioma Coalition.

OHare P, Cooney T, de Blank P, Gutmann D, Kieran M, Milde T Neuro Oncol. 2024; 26(8):1357-1366.

PMID: 38743009 PMC: 11300023. DOI: 10.1093/neuonc/noae074.

NF1 mutation-driven neuronal hyperexcitability sets a threshold for tumorigenesis and therapeutic targeting of murine optic glioma.

Anastasaki C, Chatterjee J, Koleske J, Gao Y, Bozeman S, Kernan C Neuro Oncol. 2024; 26(8):1496-1508.

PMID: 38607967 PMC: 11300021. DOI: 10.1093/neuonc/noae054.

Clinicopathological analysis of BRAF and non-BRAF MAPK pathway-altered gliomas in paediatric and adult patients: a single-institution study of 40 patients.

Ali R, Almanabri M, Ali N, Alsaber A, Khalifa N, Hussein R J Clin Pathol. 2024; 78(3):177-186.

PMID: 38195220 PMC: 11874301. DOI: 10.1136/jcp-2023-209318.

Pediatric low-grade glioma: State-of-the-art and ongoing challenges.

Fangusaro J, Jones D, Packer R, Gutmann D, Milde T, Witt O Neuro Oncol. 2023; 26(1):25-37.

PMID: 37944912 PMC: 10768984. DOI: 10.1093/neuonc/noad195.

References

Huang T, Karsy M, Zhuge J, Zhong M, Liu D . B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6:30. PMC: 3646677. DOI: 10.1186/1756-8722-6-30. View

Sapkota B, Hill C, Pollack B . Vemurafenib enhances MHC induction in BRAF homozygous melanoma cells. Oncoimmunology. 2013; 2(1):e22890. PMC: 3583938. DOI: 10.4161/onci.22890. View

Jones D, Gronych J, Lichter P, Witt O, Pfister S . MAPK pathway activation in pilocytic astrocytoma. Cell Mol Life Sci. 2011; 69(11):1799-811. PMC: 3350769. DOI: 10.1007/s00018-011-0898-9. View

Drobysheva A, Klesse L, Bowers D, Rajaram V, Rakheja D, Timmons C . Targeted MAPK Pathway Inhibitors in Patients With Disseminated Pilocytic Astrocytomas. J Natl Compr Canc Netw. 2017; 15(8):978-982. DOI: 10.6004/jnccn.2017.0139. View

Schreck K, Morin A, Zhao G, Allen A, Flannery P, Glantz M . Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAF-Mutant Human Glioma. Clin Cancer Res. 2021; 27(22):6197-6208. PMC: 8595717. DOI: 10.1158/1078-0432.CCR-21-2660. View

Nicolaides T, Nazemi K, Crawford J, Kilburn L, Minturn J, Gajjar A . Phase I study of vemurafenib in children with recurrent or progressive BRAF mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002). Oncotarget. 2020; 11(21):1942-1952. PMC: 7260122. DOI: 10.18632/oncotarget.27600. View

Villanueva J, Infante J, Krepler C, Reyes-Uribe P, Samanta M, Chen H . Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. Cell Rep. 2013; 4(6):1090-9. PMC: 3956616. DOI: 10.1016/j.celrep.2013.08.023. View

Rush S, Foreman N, Liu A . Brainstem ganglioglioma successfully treated with vemurafenib. J Clin Oncol. 2013; 31(10):e159-60. DOI: 10.1200/JCO.2012.44.1568. View

Glen C, Tan Y, Waterston A, Evans T, Jones R, Petrie M . Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors: State-of-the-Art Review. JACC CardioOncol. 2022; 4(1):1-18. PMC: 9040125. DOI: 10.1016/j.jaccao.2022.01.096. View

10.

Leaver K, Zhang N, Ziskin J, Vogel H, Recht L, Thomas R . Response of metastatic glioma to vemurafenib. Neurooncol Pract. 2019; 3(4):268-271. PMC: 6657395. DOI: 10.1093/nop/npv054. View

11.

Koumaki K, Kontogianni G, Kosmidou V, Pahitsa F, Kritsi E, Zervou M . BRAF paradox breakers PLX8394, PLX7904 are more effective against BRAFV600Ε CRC cells compared with the BRAF inhibitor PLX4720 and shown by detailed pathway analysis. Biochim Biophys Acta Mol Basis Dis. 2021; 1867(4):166061. DOI: 10.1016/j.bbadis.2020.166061. View

12.

Fangusaro J, Onar-Thomas A, Poussaint T, Wu S, Ligon A, Lindeman N . Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol. 2019; 20(7):1011-1022. PMC: 6628202. DOI: 10.1016/S1470-2045(19)30277-3. View

13.

Lavoie H, Therrien M . Regulation of RAF protein kinases in ERK signalling. Nat Rev Mol Cell Biol. 2015; 16(5):281-98. DOI: 10.1038/nrm3979. View

14.

Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B . The Different Mechanisms of Cancer Drug Resistance: A Brief Review. Adv Pharm Bull. 2017; 7(3):339-348. PMC: 5651054. DOI: 10.15171/apb.2017.041. View

15.

Sen S, Tanaka R, Khatua S, Zaky W, Janku F, Penas-Prado M . Dual inhibition of BRAF and mTOR in -mutant pediatric, adolescent, and young adult brain tumors. Cold Spring Harb Mol Case Stud. 2020; 6(4). PMC: 7476413. DOI: 10.1101/mcs.a005041. View

16.

Ferlay J, Parkin D, Steliarova-Foucher E . Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010; 46(4):765-81. DOI: 10.1016/j.ejca.2009.12.014. View

17.

Robert C, Grob J, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E . Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med. 2019; 381(7):626-636. DOI: 10.1056/NEJMoa1904059. View

18.

Lassaletta A, Stucklin A, Ramaswamy V, Zapotocky M, McKeown T, Hawkins C . Profound clinical and radiological response to BRAF inhibition in a 2-month-old diencephalic child with hypothalamic/chiasmatic glioma. Pediatr Blood Cancer. 2016; 63(11):2038-41. DOI: 10.1002/pbc.26086. View

19.

Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian Z, Du J . Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012; 487(7408):500-4. PMC: 3711467. DOI: 10.1038/nature11183. View

20.

Sun C, Bernards R . Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies. Trends Biochem Sci. 2014; 39(10):465-74. DOI: 10.1016/j.tibs.2014.08.010. View